

The Manager
Company Announcements Office
ASX Limited

LBT INNOVATIONS APPOINTS CHIEF FINANCIAL OFFICER

Adelaide, 28 August 2014: Medical technology company LBT Innovations Limited (ASX: LBT) is pleased to announce that it has appointed Mr Daniel Hill as Chief Financial Officer, effective from 25 August 2014.

Mr Hill brings significant financial, accounting and business development experience to LBT as the company embarks on a critical period of regulatory compliance and product development preceding the global launch of its Automated Plate Assessment System (APAS).

"We are delighted to have found such an experienced and highly respected CFO to help us develop the long-term financial and risk management strategies that will be vital to our sustained growth," said LBT Chief Executive Officer, Lusia Guthrie.

Daniel Hill has worked as a director, CFO or company secretary for a variety of companies in the construction, technology and financial services sectors. He also serves as CFO of Terra Rossa Capital, a \$20m venture capital fund with a life sciences focus, and Investment Manager at the \$34 million Paragon Private Equity Fund. His current directorships include power industry supplier, AEM Cores, and ultrasound technology developer, Cavitus Pty Ltd.

Mr Hill holds a Master of Business Administration from Adelaide University and a Bachelor of Accountancy from the University of South Australia, and is a member of the Institute of Chartered Accountants and the Governance Institute of Australia. He will initially work at LBT in a part-time capacity alongside Company Secretary, Jamie Dreckow.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company was formed in 2004 and listed on the Australian Securities Exchange on 31 July 2006 (ASX: LBT).

LBT has an agreement with French diagnostics company bioMérieux to manufacture and market LBT's MicroStreak® technology for the automated streaking of culture plates in routine microbiology testing (now sold as PREVI® Isola). LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories in the US, Australia, China, Japan, Korea, the Middle East, UK and multiple European countries.

LBT has a second breakthrough technology, APAS® (Automated Plate Assessment System) is nearing market. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au